目的 观察贝伐珠单抗注射液联合新辅助化疗治疗乳腺癌的临床疗效及安全性.方法 将102例乳腺癌患者随机分为对照组和试验组,每组51例.对照组予以5-氟尿嘧啶每次500 mg· m-2,第1 天,静脉注射+环磷酰胺每次500 mg· m-2,第1,8天,静脉注射+表阿霉素每次50 mg· m-2,第1天,静脉注射;试验组在对照组治疗的基础上,予以贝伐珠单抗每次15 mg· kg -1,第1天,静脉滴注. 2组患者1个疗程均为21 d,均治疗3个疗程.比较2组患者的临床疗效,p53,Ki-67,基质金属蛋白酶-2(MMP-2),MMP-9表达阳性率,以及药物不良反应的发生情况.结果 治疗后,试验组和对照组的总有效率分别为70.59%(36例/51例)和50.98%(26例/51例),差异有统计学意义(P<0.05).治疗后,试验组和对照组的p53阳性率分别为39.22%(20例/51例)和60.78%(31例/51例),Ki-67阳性率分别为27.45%(14例/51例)和47.06%(24例/51例), MMP -2 阳性率分别为25.49%(13 例/51 例)和45.10%(23 例/51例),MMP-9阳性率分别为27.45%(14例/51例)和47.06%(24例/51例),差异均有统计学意义(均P0.05).结论 贝伐珠单抗注射液联合新辅助化疗治疗乳腺癌的临床疗效确切,其能显著下调患者p53、Ki-67、MMP-2和MMP-9表达,且不增加药物不良反应的发生率.“,”Objective To observe the clinical efficacy and safety of be-vacizumab injection combined with neoadjuvant chemotherapy in the treatment of breast cancer.Methods A total of 102 patients of breast cancer were randomly divided into control and treatment groups with 51 cases per group.Control group was given 5 -fluorouracil 500 mg· m-2per time, day 1, intravenous injection +cyclophosphamide 50 mg· m-2per time, day 1, 8, intravenous injection +epirubicin 50 mg· m-2, day 1, intrave-nous injection.Treatment group received 15 mg· kg -1bevacizumab per time, day 1, intravenous injection, on the basis of control group.Two groups were treated for 3 cycles with 21 days per cycle.The clinical effi-cacy, the positive expression rates of p53, Ki-67, matrix metalloprotei-nase-2 ( MMP -2 ) and MMP -9, and adverse drug reactions were compared between two groups.Results After treatment, total effective rates of treatment and control groups were 70.59%(36 cases /51 cases) and 50.98%(26 cases /51cases) with significant difference (P<0.05).After treat-ment, the positive expression rates of treatment and control groups were compared : p53 were 39.22%(20 cases /51 cases) and 60.78%(31 cases /51 cases), Ki-67 were 27.45%(14 cases /51 cases) and 47.06%(24 cases /51 cases), MMP-2 were 25.49%(13 cases /51 cases) and 45.10%(23 cases /51 cases), MMP-9 were 27.45%(14 cases /51 cases) and 47.06%(24 cases /51 cases), the differences were statistically significant (all P0.05).Conclusion Bevacizumab injection combined with neoadjuvant chemothe-rapy has a definitive clinical efficacy in the treatment of breast cancer , which can significantly reduce the expressions of p53, Ki-67, MMP-2 and MMP-9, without increasing the incidence of adverse drug reactions .